Introduction
============

The cryopyrin-associated periodic syndromes (CAPS) are characterized by recurrent episodes of systemic inflammation. CAPS is caused by mutations in the *NLRP3* gene encoding cryopyrin, an important component of the NLRP3 inflammasome that activates caspase-1 resulting in inflammation by excessive production of IL-1β and others. A diagnostic dilemma is often encountered in patients with unspecific inflammatory symptoms like fatigue, muscle pain, arthralgia or slight hearing loss and low penetrance variants in *NLRP3 / CIAS* with an inconsistent clinical phenotype. The analysis of IL-1β in the serum did not prove to be a valid diagnostic test in these individuals.

Objectives
==========

In this study we sought to investigate, if a functional inflammasome activation assay discriminates between genetically proven CAPS patients, patients with low penetrance *NLRP3* variants and healthy controls.

Methods
=======

The study population consisted of 16 patients with genetically proven Muckle-Wells syndrome, 9 patients with low penetrance *NLRP3* variants (V198M, Q703K and E627G) and 14 healthy controls. Concentrations of IL-1β, IL-1α, IL-18, and Caspase-1 were quantified in cell culture supernatants after inflammasome stimulation with LPS and LPS + ATP for several timepoints.

Results
=======

After 4h of LPS stimulation, secretion of NLRP3 inflammasome products (IL-1β, IL-1α, IL-18) and Caspase-1 were potently increased in MWS patients, whereas there was no increase in low penetrance *NLRP3* variants and healthy controls (for IL-1β p \< 0.001 and p \< 0.001, respectively). Minor differences were still detected at later timepoints and for LPS + ATP stimulation.

Conclusion
==========

Our functional inflammasome activation assay discriminates between genetically proven CAPS patients and patients with low penetrance *NLRP3* variants. This assay might add to the decision, which individuals presumably benefit from an anti-IL-1 therapy.
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